298 related articles for article (PubMed ID: 8666168)
21. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
[TBL] [Abstract][Full Text] [Related]
22. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
[TBL] [Abstract][Full Text] [Related]
23. Effects of anti-estrogens on bone in castrated and intact female rats.
Jordan VC; Phelps E; Lindgren JU
Breast Cancer Res Treat; 1987 Oct; 10(1):31-5. PubMed ID: 3689979
[TBL] [Abstract][Full Text] [Related]
24. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene preserves bone strength and bone mass in ovariectomized rats.
Turner CH; Sato M; Bryant HU
Endocrinology; 1994 Nov; 135(5):2001-5. PubMed ID: 7956922
[TBL] [Abstract][Full Text] [Related]
26. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Sato M; Kim J; Short LL; Slemenda CW; Bryant HU
J Pharmacol Exp Ther; 1995 Mar; 272(3):1252-9. PubMed ID: 7891341
[TBL] [Abstract][Full Text] [Related]
28. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
30. Molecular determinants of tissue selectivity in estrogen receptor modulators.
Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
[TBL] [Abstract][Full Text] [Related]
31. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain.
Landry M; Lévesque D; Di Paolo T
Neuroendocrinology; 2002 Oct; 76(4):214-22. PubMed ID: 12411738
[TBL] [Abstract][Full Text] [Related]
32. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
33. Estrogen-induced genes in the uterus of ovariectomized rats and their regulation by droloxifene and tamoxifen.
Rivera-Gonzalez R; Petersen DN; Tkalcevic G; Thompson DD; Brown TA
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):13-24. PubMed ID: 9569006
[TBL] [Abstract][Full Text] [Related]
34. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats.
Wu X; Glinn MA; Ostrowski NL; Su Y; Ni B; Cole HW; Bryant HU; Paul SM
Brain Res; 1999 Nov; 847(1):98-104. PubMed ID: 10564741
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
36. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
37. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 1997 Dec; 120(2):165-71. PubMed ID: 9461033
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
39. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene.
Le Saux M; Di Paolo T
J Psychiatry Neurosci; 2005 Mar; 30(2):110-7. PubMed ID: 15798786
[TBL] [Abstract][Full Text] [Related]
40. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Bryant HU; Dere WH
Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
